ASCIA News
-
Supply update - EpiPen® Jr 150 microgram adrenaline (epinephrine) autoinjector
25 February 2020: Mylan Australia has advised that there has been sufficient supply of EpiPen® Jr 150 microgram adrenaline (epinephrine) autoinjectors since early February 2020 at wholesalers and at Mylan’s warehouse to meet current patient needs in Australia. Orders from wh... -
Pesto products recalled due to peanut contamination
21 February 2020: There have been several pesto products recalled in recent weeks because they contain an undeclared allergen (peanut). The peanuts were in one of the ingredients (cashews) used in these products. Allergy & Anaphylaxis Australia (A&AA) has worked with Food St... -
Updated ASCIA anaphylaxis e-training courses
20 February 2020: All versions of ASCIA anaphylaxis e-training courses have been updated in 2020 to include recent changes to ASCIA Action Plans and Guidelines. These courses are available at: Schools and early childhood education/care - www.allergy.org.au/patients/anaphylax... -
Venom Immunotherapy (VIT) Product Supply Update
19th February 2020: Hymenoptera® honey bee, paper wasp nad yellow jacket venom products are currently all in stock in Australia and New Zealand. However, the manufacturer of Hymenoptera® venom products (Jubilant HollisterStier LLC) has advised Stallergenes Greer of a critica... -
Updated 2020 versions of ASCIA Action Plans are now available
30 January 2020: ASCIA Action Plans for Anaphylaxis (RED) and ASCIA Action Plan for Allergic Reactions (GREEN) have been updated in January 2020 and are available at www.allergy.org.au/hp/anaphylaxis/ascia-action-plan-for-anaphylaxis Whilst the 2020 ASCIA Action Plans are th... -
ASCIA Highlights 2019
3 January 2020: As we enter a new decade in 2020, we take this opportunity to wish you a happy new year and reflect on the highlights of 2019. There were several highlights in 2019 for ASCIA, including: Highly acclaimed and successful meetings - ASCIA Annual Conference, ASCI... -
EpiPen® supply update
2 January 2020: Mylan, the supplier of 150 mcg EpiPen® Jr and 300 mcg EpiPen® adrenaline (epinephrine) autoinjectors in Australia and New Zealand, recently advised the Therapeutic Goods Administration (TGA) of the outcomes of testing of EpiPen® products. Meridian Medical Tec... -
NPS MedicineWise Immunoglobulin Consortium
16 December 2019: A new grant will fund a project which will increase national efforts to improve health outcomes for patients prescribed immunoglobulin products. This project involves the National Prescribing Service (NPS) MedicineWise and a consortium of health organisatio...
About ASCIA
ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases
Quick Links
About ASCIA
ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...
The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...
Disclaimer I Privacy
The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...
ASCIA respects your privacy. Read our privacy policy here...
Sponsors | Advertising
ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.
The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.
Accreditiation
This site complies with the HONcode standard for trustworthy health information: verify here.